A former Pfizer executive joins Eloxx's board

Eloxx Pharmaceuticals (NASDAQ:ELOX) received FDA clearance to start a Phase 2 trial for exaluren, a treatment for autosomal dominant polycystic kidney disease (ADPKD). The EXPRESS trial will enroll 60 adults with nonsense mutations, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation and accelerated approval. Exaluren has orphan drug designation in the U.S. and Europe. ADPKD affects 160,000-200,000 people in the U.S.

Guggenheim reaffirmed its Buy rating on Eloxx Pharma, setting a $40 price target, suggesting a 200% upside from the recent close. The firm cites strong clinical trial design and experienced leadership as key positives for the company.

Eloxx Pharmaceuticals (ELOX) finalized its Phase 2 trial design for exaluren in treating autosomal dominant polycystic kidney disease. The global trial will enroll 60 adults, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas as Chief Medical Officer. Exaluren has orphan drug designations in the U.S. and Europe.

Eloxx Pharmaceuticals (ELOX) finalized its EXPRESS Phase 2 study design for treating nonsense-mutation ADPKD with exaluren, expecting first patient dosing in 3Q 2027 and topline data in 1H 2029. The study will enroll 60 patients, with htTKV growth as the primary endpoint. The FDA noted that a substantial htTKV effect could support Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas, M.D., as Chief Medical Officer.

Eloxx Pharmaceuticals completed a 52-week Phase 2 study design for exaluren in 60 ADPKD patients, with dosing expected in 3Q 2027 and results in 1H 2029. The company also appointed T.R. Srinivas, M.D., as Chief Medical Officer. According to Eloxx, a significant and lasting effect on htTKV and supportive eGFR and safety data would be required for accelerated regulatory pathways.

Eloxx Pharmaceuticals (ELOX) finalized its EXPRESS Phase 2 trial design for exaluren, a potential treatment for inherited kidney disease ADPKD. The 52-week study will enroll 60 patients, with topline data expected in 1H 2029. The FDA noted that a substantial htTKV effect could support Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas as Chief Medical Officer to lead its rare kidney programs. Exaluren has received orphan drug designations in the US and Europe.